Board Change • May 20
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Mar 24
Novonesis A/S Approves Dividend on A and B Share Novozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. Announcement • Feb 27
Novozymes A/S, Annual General Meeting, Mar 23, 2026 Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark Announcement • Nov 06
Novozymes A/S Revises Earnings Guidance for the Year 2025 Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%). Announcement • Jun 02
Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR). Novonesis A/S (CPSE:NSIS B) agreed to acquire remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) for €1.5 billion on February 11, 2025. Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities. The transaction is accretive to Novonesis' revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies. dsm-firmenich expects to receive approximately €1.4 billion net in cash, after transaction costs and capital gains tax, and anticipates a book profit on the transaction to be recognized upon closing. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network. For the period ending December 31, 2024, Feed Enzymes Alliance of DSM-Firmenich AG reported total revenue of €300 million. Novonesis will continue the long-term supply relationship with DSM-Firmenich for their premix business. The acquisition is 100% debt financed and fully committed.
The transaction is subject to regulatory approvals, the transaction is expected to close in the course of 2025. The expected strong cash generation will allow for deleveraging to the current target range of 1.3 to 1.7x net debt divided by EBITDA within the next 2 years. It is expected that the transaction will have no impact on dividend payouts.
Gordon Dyal & Co acted as financial advisor, Baker McKenzie acted a legal advisor and financing is obtained through BNP Paribas to Novonesis. Piper Sandler acted as financial advisor to DSM-Firmenich AG.
Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) on June 2, 2025. All regulatory approvals have been achieved. Gregory Crookes, Stephanie Horowitz, Pieter Leefers, Chris In t Veld, Marc Besen, Jurre Jurriëns, Gunnar Sachs, Claudia Milbradt, Nicolas Hohn-Hein, Floris van de Bult, Florence Aubonnet, Wijnanda Rutten and Michiel Sunderman of Clifford Chance Partnerschaftsgesellschaft, Clifford Chance France and Clifford Chance LLP acted as legal advisor to DSM-Firmenich AG. Announcement • May 08
Novonesis A/S Maintains Earnings Guidance for the Year 2025 Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries). Announcement • Apr 07
Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026 Novonesis A/S announced that they will report fiscal year 2025 results on Feb 25, 2026 Announcement • Mar 06
Novonesis A/S Announces Board Changes The employees of Novonesis A/S have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly elected. Lars Bo Køppler, Technician - newly elected and Frederikke Rose Spenner, Production Engineer - newly elected. As alternates to the employee representatives to the Board of Directors, the employees elected Mikael Barfred, Heidi Gelt and Ida Carlsen Virklund. The newly elected employee representatives will join the Board of Directors following the Annual General Meeting of Novonesis on April 3, 2025. At the same event, the term of election for the former employee representatives, Lena Bech Holskov, Anders Hentze Knudsen, and Jens Øbro will end. The term of Board Observer Kim Ib Sørensen will also end following the Annual General Meeting of Novonesis on April 3, 2025. Announcement • Feb 21
Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025 Novonesis A/S announced that Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Jacob joined Chr. Hansen in 2006 and became a member of the Corporate Leadership Team in 2013. During his tenure in Chr. Hansen, Jacob has held multiple global sales and business unit leadership positions and since 2019 been responsible for the Food Cultures & Enzymes business unit, before entering his current role in Novonesis. Announcement • Dec 17
Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024 Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Sharon James has expressed her gratitude for the opportunity to serve together with the Board and Management team with strong confidence in Novonesis’ future leadership and strategic vision. Announcement • Oct 21
Novonesis A/S Announces Board Changes Novonesis A/S announced that Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, has decided to step down as a board member. The first alternate, Lena Bech Holskov (Safety Adviser, OHS) has replaced Anne Breum as employee-elected board member of the Company for the remaining period of the current four-year election term ending following the annual general meeting of the Company to be held on April 3, 2025. Announcement • Aug 28
Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024 Novonesis approved interim dividend for 2024 at DKK 2.00 per share (EUR 0.27). The dividend will be disbursed on September 3, 2024, with August 29, 2024, as the last trading day with dividend. Announcement • May 03
Novonesis Provides Sales Guidance for the Year 2024 Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth. Announcement • May 01
Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023 Novozymes A/S announced at the AGM held on April 30, 2024, approved distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022. Announcement • Apr 09
Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023 Novozymes A/S announced that at its AGM to be held on April 30, 2024, The distribution of profit will be addressed at the meeting and the board of directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 to December 31) of 2023. This equals a pay-out ratio of 53.2% of the company’s adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result. Announcement • Mar 23
Novonesis Provides Earnings Guidance for the Year 2024 Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth. Announcement • Jun 30
Novozymes A/S, Annual General Meeting, Mar 13, 2024 Novozymes A/S, Annual General Meeting, Mar 13, 2024. 
